Drug Profile
SB 200 family - Symic Bio
Alternative Names: SB-200Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator SYMIC Biomedical
- Developer Symic Bio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Breast-cancer in USA
- 28 Sep 2020 No recent reports of development identified for research development in Non-small-cell-lung-cancer in USA
- 28 Sep 2020 No recent reports of development identified for research development in Ovarian-cancer in USA